8-K 1 d691228d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 10, 2014

 

 

MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

Delaware   0-26642   87-0494517
(State or other
jurisdiction of
incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

320 Wakara Way

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 584-3600

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


ITEM 7.01 Regulation FD Disclosure.

As previously disclosed, in July 2013 we and other BRCA patent owners filed a complaint against Ambry Genetics Corporation in the United States District Court for the District of Utah, alleging that Ambry’s testing services infringe various patent claims owned by the BRCA patent owners which relate to the BRCA1 and BRCA2 genes, and seeking a preliminary injunction to prevent Ambry from selling these testing services pending a final decision on the merits of the case.

On March 10, 2014, the District Court denied our motion for preliminary injunctive relief. We believe the BRCA patents at issue in this case are valid, enforceable and infringed, and are confident we will prevail based on the full evidence. A trial date has not been scheduled.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MYRIAD GENETICS, INC.
Date: March 11, 2014     By:   /s/ Peter D. Meldrum
      Peter D. Meldrum
      President and Chief Executive Officer